

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Thomas M. Jessell, et al.
U.S. Serial No. : Not Yet Known (Continuation Application
of PCT/US99/22517, filed 29 September
1999)
Filed : Herewith
For : GENE ENCODING MNR2 AND USES THEREOF

1185 Avenue Of The Americas
New York, New York 10036
March 29, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231
Box: Patent Application

Sir:

PRELIMINARY AMENDMENT TO THE ACCOMPANYING CONTINUATION
APPLICATION FILED UNDER 37 C.F.R. §1.53

Applicants request that the following amendment be made in the
above-identified application:

In the Specification:

On page 1, after the title, please delete the first paragraph and
insert the following new paragraph:

--This application is a continuation of PCT International
Application No. PCT/US99/22517, filed 29 September 1999,
designating the United States of America, which is a
continuation-in-part and claims priority of U.S. Serial No.
09/162,524, filed September 29, 1998, the contents of which
are hereby incorporated by reference into the present
application.--

In the Claims:

Please cancel claims 2-5, 7-13, 15, 17, 19-20, 22-23, 25-26, 28-
33, 35-37, 39-43, 46-47, 51, 53-55, 58-59, 62-65, 67-73, 75, 77,
79-80, 82-83, 85-86, 88-93, 95-97, 99-103, 106-107, 111, 113-115,
and 118-119 without prejudice or disclaimer to applicants' right
to pursue the subject matter of these claims in a future
continuation or divisional application.

Please amend claims 16, 34, 44-45, 48, 76, 94, 104-105, and 108
as follows:

Thomas M. Jessell, et al.
U.S. Serial No. : Not Yet Known
(Continuation Application of
PCT/US99/22517, filed 29 September 1999)
Filed: Herewith
Page 2

16. (Amended) A method of producing a polypeptide having the biological activity of a mammalian MNR2 which comprises growing the host cells of claim 14 under suitable conditions permitting production of the polypeptide.
34. (Amended) An antibody directed to an epitope of an MNR2 protein of claim 27.
44. (Amended) A method of producing the isolated protein of claim 27 which comprises:
- (a) inserting a nucleic acid molecule encoding a MNR2 protein into a suitable vector;
 - (b) introducing the resulting vector into a suitable host cell;
 - (c) selecting the introduced host cell for the expression of the MNR2 protein;
 - (d) culturing the selected cell to produce the MNR2 protein; and
 - (e) recovering the MNR2 protein produced
45. (Amended) A method of inducing differentiation of somatic motoneurons in a subject comprising administering to the subject the purified MNR2 protein of claim 27 in an amount effective to induce differentiation of somatic motor neurons in the subject.
48. (Amended) A pharmaceutical composition comprising a purified MNR2 protein of claim 27 and a pharmaceutically acceptable carrier.
76. (Amended) A method of producing a polypeptide having the biological activity of a mammalian HB9 which comprises growing the host cells of claim 74 under suitable conditions permitting production of the polypeptide.
94. (Amended) An antibody directed to an epitope of an HB9 protein of claim 87.

Thomas M. Jessell, et al.
U.S. Serial No. : Not Yet Known
(Continuation Application of
PCT/US99/22517, filed 29 September 1999)
Filed: Herewith
Page 3

104. (Amended) A method of producing the isolated protein of claim 87 which comprises:

- (a) inserting a nucleic acid molecule encoding a HB9 protein into a suitable vector;
- (b) introducing the resulting vector into a suitable hostcell;
- (c) selecting the introduced host cell for the expression of the HB9 protein;
- (d) culturing the selected cell to produce the HB9 protein; and
- (e) recovering the HB9 protein produced.

105. (Amended) A method of inducing differentiation of somatic motor neurons in a subject comprising administering to the subject the purified HB9 protein of claim 87 in an amount effective to induce differentiation of somatic motor neurons in the subject.

108. (Amended) A pharmaceutical composition comprising a purified HB9 protein of claim 87 and a pharmaceutically acceptable carrier.

REMARKS

This application is a continuation of PCT International Application No. PCT/US99/22517, filed 29 September 1999, designating the United States of America, which is a continuation-in-part and claims priority of U.S. Serial No. 09/162,524, filed September 29, 1998. Accordingly, the parent application, PCT International Application No. PCT/US99/22517, is pending today in the United States of America pursuant to 35 U.S.C. §363, and the subject continuation application is co-pending therewith in fulfillment of the provisions of 35 U.S.C. §120.

By this Preliminary Amendment, applicants have hereinabove amended the specification on page 1 to insert the continuation data. Applicants maintain that the amendments made hereinabove do not raise any issue of new matter. Accordingly, applicants respectfully request entry of the Amendment.

[illegible]

John P. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Amended Claims:

16. (Amended) A method of producing a polypeptide having the biological activity of a mammalian MNR2 which comprises growing the host cells of claim[15] 14 under suitable conditions permitting production of the polypeptide.
34. (Amended) [A monoclonal] An antibody directed to an epitope of an MNR2 protein of claim [33]27.
44. (Amended) A method of producing the isolated protein of [either of] claim[s] 27 [or 28] which comprises:
- (a) inserting a nucleic acid molecule encoding a MNR2 protein into a suitable vector;
 - (b) introducing the resulting vector into a suitable host cell;
 - (c) selecting the introduced host cell for the expression of the MNR2 protein;
 - (d) culturing the selected cell to produce the MNR2 protein; and
 - (e) recovering the MNR2 protein produced.
45. (Amended) A method of inducing differentiation of somatic motoneurons in a subject comprising administering to the subject the purified MNR2 protein of [either of] claim[s] 27 [or 28] in an amount effective to induce differentiation of somatic motor neurons in the subject.
48. (Amended) A pharmaceutical composition comprising a purified MNR2 protein of [either of] claim[s] 27 [or 28] and a pharmaceutically acceptable carrier.
76. (Amended) A method of producing a polypeptide having the biological activity of a mammalian HB9 which comprises growing the host cells of claim [65] 74 under suitable conditions permitting production of the polypeptide.
94. (Amended) [A monoclonal] An antibody directed to an epitope of an HB9 protein of claim [93] 87.

104. (Amended) A method of producing the isolated protein of [either of] claim[s] 87 [or 88] which comprises:

- (a) inserting a nucleic acid molecule encoding a HB9 protein into a suitable vector;
- (b) introducing the resulting vector into a suitable host cell;
- (c) selecting the introduced host cell for the expression of the HB9 protein;
- (d) culturing the selected cell to produce the HB9 protein; and
- (e) recovering the HB9 protein produced.

105. (Amended) A method of inducing differentiation of somatic motor neurons in a subject comprising administering to the subject the purified HB9 protein of [either of] claim[s] 87 [or 88] in an amount effective to induce differentiation of somatic motor neurons in the subject.

108. (Amended) A pharmaceutical composition comprising a purified HB9 protein of [either of] claim[s] 87 [or 88] and a pharmaceutically acceptable carrier.